Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreas Cancer: early-phase trial registry
30 of 55 indexed Pancreas Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #254 of 28,707 conditions by registered trial count.
55 US clinical trials · 30 currently recruiting · #254 of 28,707 conditions by registered trial count
Pancreas Cancer: 55 US clinical trials tracked, 30 recruiting.
Pancreas Cancer is the subject of 55 registered US clinical trials on ClinicalTrials.gov, 30 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 29 in Phase 1-2 (earlier-stage). The most active sponsor is A2 Biotherapeutics, running 3 of these trials.
Enrollment posture brief
Registry condition pancreas-cancer
OPEN 30 | RECR 55% | LATE 2 | EARLY 29 | RANK #254 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)
Pancreas Cancer lists 30 open slots (55% of 55 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreas Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreas Cancer is recruiting above its size-band peers.
30 of 55 indexed trials (54.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pancreas Cancer trials is spread across many organizations.
A2 Biotherapeutics accounts for 3 of 55 trials (5.5%). 41 distinct sponsors appear on at least one study for this condition label.
-
Typical Pancreas Cancer enrolment sits around 60 participants.
Median target enrolment is 60 among the 55 trials that report a genuine target (sentinel values excluded). 32 of those (58.2%) plan for fewer than 100 participants.
-
Pancreas Cancer research is mostly interventional.
42 interventional and 13 observational studies make up this index (76.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
55 total, page 1 of 2
Pancreatic Cancer Early Detection Consortium
Arbor Research Collaborative for Health
NCT04970056
The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins University
NCT02000089
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
Persephone Biosciences
NCT04638751
Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts
Johns Hopkins University
NCT04473794
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
National Cancer Institute (NCI)
NCT01915225
Pancreas Registry and High Risk Registry
Icahn School of Medicine at Mount Sinai
NCT02775461
ExoLuminate Study for Early Detection of Pancreatic Cancer
Biological Dynamics
NCT05625529
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06051695
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
University of Colorado, Denver
NCT05517811
Stereotactic Magnetic Resonance Guided Radiation Therapy
Dana-Farber Cancer Institute
NCT04115254
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
NCT04907643
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Bicara Therapeutics
NCT04429542
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT06545942
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
NCT06263088
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A2 Biotherapeutics
NCT04981119
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics
NCT06582017
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
M.D. Anderson Cancer Center
NCT06593431
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Massachusetts General Hospital
NCT04485286
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
Washington University School of Medicine
NCT05975593
ctDNA Assay in Patients With Resectable Pancreatic Cancer
University of Oklahoma
NCT05052671
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
Baptist Health South Florida
NCT05679674
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence
Medical College of Wisconsin
NCT06228599
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Mayo Clinic
NCT04605913
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
Susan E. Bates
NCT05241249
Collection of Circulating Biomarkers in Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
NCT05743049
Pancreatic Cancer & Surgical Resection
Methodist Health System
NCT05170802
Autologous CAR-T Cells Targeting B7-H3 in PDAC
UNC Lineberger Comprehensive Cancer Center
NCT06158139
Promoting CT Engagement for Pancreatic Cancer With App
UNC Lineberger Comprehensive Cancer Center
NCT06252545
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
University of Virginia
NCT06479239
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
University of Louisville
NCT03484299
Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes
Memorial Sloan Kettering Cancer Center
NCT02917798
Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement
Massachusetts General Hospital
NCT03716531
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
TORL Biotherapeutics
NCT05156866
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT05736731
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
NCT04902872
Pancreatic Cancer Early Detection Program
White Plains Hospital
NCT02206360
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
TORL Biotherapeutics
NCT05159440
CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
Anup Kasi
NCT05121038
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Washington University School of Medicine
NCT04331041
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
Verastem
NCT05669482
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
NCT05704985
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
University of Cincinnati
NCT04594772
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
University of Kansas Medical Center
NCT05915351
A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
Andrew Hendifar, MD
NCT05336266
Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer
University of Kansas Medical Center
NCT05638698
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
University of Nebraska
NCT05220046
An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma
Memorial Sloan Kettering Cancer Center
NCT04837833
A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
M.D. Anderson Cancer Center
NCT05497778
A Supervised Prehabilitation Program for Patients With Pancreatic Cancer
Cedars-Sinai Medical Center
NCT05692323
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
HonorHealth Research Institute
NCT05068752
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 2 | 8 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreas Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreas Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreas Cancer page
55 registered trials, 30 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 30 Pancreas Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- A2 Biotherapeutics sponsors the most Pancreas Cancer trials on record, review their full trial history before evaluating a specific study. See A2 Biotherapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreas Cancer condition card totals 55 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.